Market Size of Global Anxiety Disorders and Depression Treatment Industry
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 21.51 Billion |
| Market Size (2029) | USD 27.87 Billion |
| CAGR (2024 - 2029) | 5.32 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Anxiety Disorders & Depression Treatment Market Analysis
The Global Anxiety Disorders and Depression Treatment Market size is estimated at USD 21.51 billion in 2024, and is expected to reach USD 27.87 billion by 2029, growing at a CAGR of 5.32% during the forecast period (2024-2029).
The COVID-19 outbreak significantly impacted the growth due to the increased number of cases of anxiety and depression during the pandemic period. For instance, a WHO report published in March 2022 stated that in the first year of the COVID-19 pandemic, the global prevalence of anxiety and depression increased by 25% in 2021. Additionally, the Springer Journal article published in October 2021 estimated an additional 53.2 million cases of major depressive disorders globally due to the COVID-19 pandemic and an additional 76.2 million cases of anxiety disorders in 2021. Thus, the increased anxiety and depression disorders due to the pandemic had a notable impact on the market's growth over the pandemic period. In addition, the demand is expected to remain intact due to the rising awareness among the global population regarding anxiety and depression, thereby increasing the market growth over the forecast period.
Factors such as the increasing prevalence of anxiety disorders and depression, increasing awareness levels, and product launches by key market players are expected to increase the market share. For instance, in September 2021, an article published by WHO stated that depression is a common illness worldwide, with an estimated 3.8% of the population affected, including 5.0% among adults and 5.7% among adults older than 60. Approximately 280 million people in the world will have depression in 2021. Additionally, the TRV data published in 2022 mentioned that an estimated 264 million people globally experienced an anxiety disorder in 2021. Such an increasing prevalence of anxiety and depression worldwide is expected to contribute to the market's growth.
On the other hand, increasing product approvals is another factor expected to drive the market's growth. For instance, in July 2021, Alembic Pharmaceuticals received final approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Desipramine Hydrochloride tablets USP, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, and 150 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Norpramin Tablets, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, and 150 mg, of Validus Pharmaceuticals LLC. Desipramine Hydrochloride Tablets and USP are indicated for the treatment of depression.
However, the patent expiration of branded drugs will hinder the market's growth over the forecast period.
Anxiety Disorders & Depression Treatment Industry Segmentation
As per the scope, depression and some anxiety disorders can be treated with antidepressant drugs and therapy. The market includes both devices and therapy in the scope. The Anxiety Disorders and Depression Treatment Market is Segmented by Product (Antidepressant Drugs, Therapy and Devices, and Others), Indication (Obsessive-Compulsive Disorder, Major Depressive Disorder, Phobia, and Others), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (in USD million) for the above segments.
| By Product | |
| Antidepressant Drugs | |
| Therapy and Devices | |
| Others |
| By Indication | |
| Obsessive-Compulsive Disorder | |
| Major Depressive Disorder | |
| Phobia | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Anxiety Disorders and Depression Treatment Market Size Summary
The anxiety disorders and depression treatment market is poised for significant growth, driven by the increasing prevalence of these conditions globally. The COVID-19 pandemic has exacerbated the situation, leading to a notable rise in cases of anxiety and depression, which in turn has fueled demand for effective treatments. The market is characterized by a surge in awareness and the introduction of new products by key players, contributing to its expansion. The presence of major pharmaceutical companies and a robust clinical pipeline, particularly in North America, further supports the market's growth trajectory. However, challenges such as the patent expiration of branded drugs may pose obstacles to sustained market advancement.
The market landscape is competitive and partially fragmented, with several international and local companies holding significant shares. Major players like Pfizer Inc., GlaxoSmithKline, Merck & Co. Inc., Eli Lilly & Co., and Johnson & Johnson are at the forefront, driving innovation and product development. Regulatory approvals for new treatments, such as those by the US FDA, are expected to bolster market growth. The ongoing efforts to address treatment-resistant depression and the development of novel therapeutic approaches underscore the dynamic nature of the market. As awareness and demand continue to rise, the market is set to experience robust growth over the forecast period.
Global Anxiety Disorders and Depression Treatment Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Prevalence of Depression
-
1.2.2 Emerging Novel Biologics
-
-
1.3 Market Restraints
-
1.3.1 Patent Expiration of Branded Drugs
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Product
-
2.1.1 Antidepressant Drugs
-
2.1.2 Therapy and Devices
-
2.1.3 Others
-
-
2.2 By Indication
-
2.2.1 Obsessive-Compulsive Disorder
-
2.2.2 Major Depressive Disorder
-
2.2.3 Phobia
-
2.2.4 Others
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Global Anxiety Disorders and Depression Treatment Market Size FAQs
How big is the Global Anxiety Disorders and Depression Treatment Market?
The Global Anxiety Disorders and Depression Treatment Market size is expected to reach USD 21.51 billion in 2024 and grow at a CAGR of 5.32% to reach USD 27.87 billion by 2029.
What is the current Global Anxiety Disorders and Depression Treatment Market size?
In 2024, the Global Anxiety Disorders and Depression Treatment Market size is expected to reach USD 21.51 billion.
